Clinical Trials
13 trialsNCT05468359 2026-05-19
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT06096038 2026-02-20
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05201248 2025-01-07
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2 Active not recruiting
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT00003552 2024-03-04
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT05155215 2021-12-13
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
NCT02224599 2020-04-24
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Kiromic BioPharma Inc.
Phase 1/2 Terminated
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT00924001 2012-10-25
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated